当前位置: 首页 >> 检索结果
1142. Integrated metagenomic and metabolomic analysis reveals distinct gut-microbiome-derived phenotypes in early-onset colorectal cancer.
作者: Cheng Kong.;Lei Liang.;Guang Liu.;Lutao Du.;Yongzhi Yang.;Jianqiang Liu.;Debing Shi.;Xinxiang Li.;Yanlei Ma.
来源: Gut. 2023年72卷6期1129-1142页
The incidence of early-onset colorectal cancer (EO-CRC) is steadily increasing. Here, we aimed to characterise the interactions between gut microbiome, metabolites and microbial enzymes in EO-CRC patients and evaluate their potential as non-invasive biomarkers for EO-CRC.
1143. Molecular heterogeneity and commonalities in pancreatic cancer precursors with gastric and intestinal phenotype.
作者: Sven-Thorsten Liffers.;Laura Godfrey.;Lisa Frohn.;Lena Haeberle.;Aslihan Yavas.;Rita Vesce.;Wolfgang Goering.;Friederike V Opitz.;Nickolas Stoecklein.;Wolfram Trudo Knoefel.;Anna Melissa Schlitter.;Guenter Klöppel.;Elisa Espinet.;Andreas Trumpp.;Jens T Siveke.;Irene Esposito.
来源: Gut. 2023年72卷3期522-534页
Due to the limited number of modifiable risk factors, secondary prevention strategies based on early diagnosis represent the preferred route to improve the prognosis of pancreatic ductal adenocarcinoma (PDAC). Here, we provide a comparative morphogenetic analysis of PDAC precursors aiming at dissecting the process of carcinogenesis and tackling the heterogeneity of preinvasive lesions.
1146. Vitamin D receptor and STAT6 interactome governs oesophageal epithelial barrier responses to IL-13 signalling.
作者: Michael Brusilovsky.;Mark Rochman.;Tetsuo Shoda.;Michael Kotliar.;Julie M Caldwell.;Lydia E Mack.;John A Besse.;Xiaoting Chen.;Matthew T Weirauch.;Artem Barski.;Marc E Rothenberg.
来源: Gut. 2023年72卷5期834-845页
The contribution of vitamin D (VD) deficiency to the pathogenesis of allergic diseases remains elusive. We aimed to define the impact of VD on oesophageal allergic inflammation.
1147. Inactivated genotype 1a, 2a and 3a HCV vaccine candidates induced broadly neutralising antibodies in mice.
作者: Garazi Pena Alzua.;Anne Finne Pihl.;Anna Offersgaard.;Carlos Rene Duarte Hernandez.;Zhe Duan.;Shan Feng.;Ulrik Fahnøe.;Christina Sølund.;Nina Weis.;Mansun Law.;Jannick C Prentoe.;Jan Pravsgaard Christensen.;Jens Bukh.;Judith Margarete Gottwein.
来源: Gut. 2023年72卷3期560-572页
A prophylactic vaccine is needed to control the HCV epidemic, with genotypes 1-3 causing >80% of worldwide infections. Vaccine development is hampered by HCV heterogeneity, viral escape including protection of conserved neutralising epitopes and suboptimal efficacy of HCV cell culture systems. We developed cell culture-based inactivated genotype 1-3 HCV vaccine candidates to present natively folded envelope proteins to elicit neutralising antibodies.
1149. Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn's disease: systematic review and network meta-analysis.
作者: Brigida Barberio.;David J Gracie.;Christopher J Black.;Alexander C Ford.
来源: Gut. 2023年72卷2期264-274页
There are numerous biological therapies and small molecules licensed for luminal Crohn's disease (CD), but these are often studied in placebo-controlled trials, meaning relative efficacy is uncertain. We examined this in a network meta-analysis.
1150. Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic.
作者: Nicholas A Kennedy.;Malik Janjua.;Neil Chanchlani.;Simeng Lin.;Claire Bewshea.;Rachel Nice.;Timothy J McDonald.;Cressida Auckland.;Lorna W Harries.;Merlin Davies.;Stephen Michell.;Klaartje B Kok.;Christopher A Lamb.;Philip J Smith.;Ailsa L Hart.;Richard Cg Pollok.;Charlie W Lees.;Rosemary J Boyton.;Daniel M Altmann.;Shaji Sebastian.;Nicholas Powell.;James R Goodhand.;Tariq Ahmad.
来源: Gut. 2023年72卷2期295-305页
Antitumour necrosis factor (TNF) drugs impair serological responses following SARS-CoV-2 vaccination. We sought to assess if a third dose of a messenger RNA (mRNA)-based vaccine substantially boosted anti-SARS-CoV-2 antibody responses and protective immunity in infliximab-treated patients with IBD.
1152. Response to: Correspondence on "PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligence system" by Wong et al.
作者: Marietta Iacucci.;Tommaso Lorenzo Parigi.;Alina Bazarova.;Subrata Ghosh.;Vincenzo Villanacci.;Xianyong Gui.
来源: Gut. 2023年72卷4期807-808页 1155. GWAS meta-analysis of 16 790 patients with Barrett's oesophagus and oesophageal adenocarcinoma identifies 16 novel genetic risk loci and provides insights into disease aetiology beyond the single marker level.
作者: Julia Schröder.;Laura Chegwidden.;Carlo Maj.;Jan Gehlen.;Jan Speller.;Anne C Böhmer.;Oleg Borisov.;Timo Hess.;Nicole Kreuser.;Marino Venerito.;Hakan Alakus.;Andrea May.;Christian Gerges.;Thomas Schmidt.;Rene Thieme.;Dominik Heider.;Axel M Hillmer.;Julian Reingruber.;Orestis Lyros.;Arne Dietrich.;Albrecht Hoffmeister.;Matthias Mehdorn.;Florian Lordick.;Gertraud Stocker.;Michael Hohaus.;Daniel Reim.;Jennis Kandler.;Michaela Müller.;Alanna Ebigbo.;Claudia Fuchs.;Christiane J Bruns.;Arnulf H Hölscher.;Hauke Lang.;Peter P Grimminger.;Dani Dakkak.;Yogesh Vashist.;Sandra May.;Siegfried Görg.;Andre Franke.;David Ellinghaus.;Sara Galavotti.;Lothar Veits.;Josef Weismüller.;Jens Dommermuth.;Udo Benner.;Thomas Rösch.;Helmut Messmann.;Brigitte Schumacher.;Horst Neuhaus.;Carsten Schmidt.;Thaddäus T Wissinowski.;Markus M Nöthen.; .; .; .;Jing Dong.;Jue-Sheng Ong.;Matthew F Buas.;Aaron P Thrift.;Thomas L Vaughan.;Ian Tomlinson.;David C Whiteman.;Rebecca Claire Fitzgerald.;Janusz Jankowski.;Michael Vieth.;Andreas Mayr.;Puya Gharahkhani.;Stuart MacGregor.;Ines Gockel.;Claire Palles.;Johannes Schumacher.
来源: Gut. 2023年72卷4期612-623页
Oesophageal cancer (EC) is the sixth leading cause of cancer-related deaths. Oesophageal adenocarcinoma (EA), with Barrett's oesophagus (BE) as a precursor lesion, is the most prevalent EC subtype in the Western world. This study aims to contribute to better understand the genetic causes of BE/EA by leveraging genome wide association studies (GWAS), genetic correlation analyses and polygenic risk modelling.
1156. SARS-CoV-2 vaccination in patients with GI and hepatobiliary carcinoma: a call for booster vaccination.
作者: Malte Benedikt Monin.;Leona Baier.;Moritz Berger.;Jens Gabriel Gorny.;Taotao Zhou.;Robert Mahn.;Farsaneh Sadeghlar.;Christian Möhring.;Kathrin van Bremen.;Christoph Boesecke.;Jürgen Rockstroh.;Christian Strassburg.;Anna-Maria Eis-Hübinger.;Maria Agnes Gonzalez-Carmona.
来源: Gut. 2023年72卷6期1227-1229页 1158. Accurate liquid biopsy for the diagnosis of non-alcoholic steatohepatitis and liver fibrosis.
作者: Giulia Angelini.;Simona Panunzi.;Lidia Castagneto-Gissey.;Francesca Pellicanò.;Andrea De Gaetano.;Maurizio Pompili.;Laura Riccardi.;Matteo Garcovich.;Marco Raffaelli.;Luigi Ciccoritti.;Ornella Verrastro.;Maria Francesca Russo.;Fabio Maria Vecchio.;Giovanni Casella.;James Casella-Mariolo.;Luigi Papa.;Pier Luigi Marini.;Francesco Rubino.;Carel W le Roux.;Stefan Bornstein.;Geltrude Mingrone.
来源: Gut. 2023年72卷2期392-403页
Clinical diagnosis and approval of new medications for non-alcoholic steatohepatitis (NASH) require invasive liver biopsies. The aim of our study was to identify non-invasive biomarkers of NASH and/or liver fibrosis.
1159. Regulatory enhancer profiling of mesenchymal-type gastric cancer reveals subtype-specific epigenomic landscapes and targetable vulnerabilities.
作者: Shamaine Wei Ting Ho.;Taotao Sheng.;Manjie Xing.;Wen Fong Ooi.;Chang Xu.;Raghav Sundar.;Kie Kyon Huang.;Zhimei Li.;Vikrant Kumar.;Kalpana Ramnarayanan.;Feng Zhu.;Supriya Srivastava.;Zul Fazreen Bin Adam Isa.;Chukwuemeka George Anene-Nzelu.;Milad Razavi-Mohseni.;Dustin Shigaki.;Haoran Ma.;Angie Lay Keng Tan.;Xuewen Ong.;Ming Hui Lee.;Su Ting Tay.;Yu Amanda Guo.;Weitai Huang.;Shang Li.;Michael A Beer.;Roger Sik Yin Foo.;Ming Teh.;Anders Jacobsen Skanderup.;Bin Tean Teh.;Patrick Tan.
来源: Gut. 2023年72卷2期226-241页
Gastric cancer (GC) comprises multiple molecular subtypes. Recent studies have highlighted mesenchymal-subtype GC (Mes-GC) as a clinically aggressive subtype with few treatment options. Combining multiple studies, we derived and applied a consensus Mes-GC classifier to define the Mes-GC enhancer landscape revealing disease vulnerabilities.
|